NCT07281001 A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
| NCT ID | NCT07281001 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Blokhin's Russian Cancer Research Center |
| Condition | HER2-positive Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-12 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-12 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
Eligibility Criteria
Inclusion Criteria: 1. Patients aged over 18 years old. 2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer. 3. Patients has received Trastuzumab Deruxtecan 4. Available medical history. Exclusion Criteria: 1. Incomplete medical history. 2. Pregnancy or breast-breeding
Contact & Investigator
Elena Artamonova
PRINCIPAL INVESTIGATOR
The Blokhin National Medical Research Center of Oncology of the Russian Ministry of Health
Frequently Asked Questions
Who can join the NCT07281001 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying HER2-positive Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07281001 currently recruiting?
Yes, NCT07281001 is actively recruiting participants. Contact the research team at tatiana.titovadoc@gmail.com for enrollment information.
Where is the NCT07281001 trial being conducted?
This trial is being conducted at Moscow, Russia.
Who is sponsoring the NCT07281001 clinical trial?
NCT07281001 is sponsored by Blokhin's Russian Cancer Research Center. The principal investigator is Elena Artamonova at The Blokhin National Medical Research Center of Oncology of the Russian Ministry of Health. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.